Guiyun Liu1, Rong Jiang1, Chenyang Xu1, Jiao Zhou1, Fengxin Liu1, Zhengwen He2, Zhigang Liu3. 1. Department of Clinical Medicine, South China University of Medicine, Hengyang Hunan 421001; Department of Radiotherapy, Hunan Cancer Hospital and Affi liated Cancer Hospital of Xiangya School of Medicine, Central South University; Key Laboratory of Translational Radiation Oncology, Changsha 410013, China. 2. Department of Neurosurgery, Hunan Cancer Hospital, Affi liated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. 3. Department of Radiotherapy, Hunan Cancer Hospital and Affi liated Cancer Hospital of Xiangya School of Medicine, Central South University; Key Laboratory of Translational Radiation Oncology, Changsha 410013, China.
Abstract
OBJECTIVE: To analyze the curative effect and prognostic factors for comprehensive therapy in patients with high-grade glioma. Methods: Patients with high-grade glioma (WHO grade III, grade IV) were chosen from July 2008 to May 2016 in the Hunan Cancer Hospital, and a retrospective analysis was performed in 64 patients with complete follow-up data. Results: The follow-up time was 3-111 (median 29.5) months, the median overall survival time was 36.00 (95% CI 22.85 to 49.16) months, the median progression-free survival time (PFS) was 21.00 (95% CI 9.72 to 32.28) months. The 1-year, 2-year, 3-year and 5-year survival rates of high-grade glioma patients were 87.50%, 56.25%, 40.63% and 17.19%, respectively. The univariate analysis of Log-Rank test and the Cox regression model analysis showed that the prognostic factors related to the prognosis of high-grade glioma patients were pathological grade, resection degree, and concurrent chemo-radiotherapy (P<0.05). Conclusion: The overall survival time, progression-free survival time and the 5-year survival rate of patients with high-grade glioma after comprehensive treatment is partially improved. The factors relevant to the prognosis of patients with high-grade glioma are pathological grade, resection degree, and concurrent chemo-radiotherapy, indicating that the glioma patients (WHO grade III) received total resection of the tumor and concurrent chemo-radiotherapy have better clinical effect.
OBJECTIVE: To analyze the curative effect and prognostic factors for comprehensive therapy in patients with high-grade glioma. Methods:Patients with high-grade glioma (WHO grade III, grade IV) were chosen from July 2008 to May 2016 in the Hunan Cancer Hospital, and a retrospective analysis was performed in 64 patients with complete follow-up data. Results: The follow-up time was 3-111 (median 29.5) months, the median overall survival time was 36.00 (95% CI 22.85 to 49.16) months, the median progression-free survival time (PFS) was 21.00 (95% CI 9.72 to 32.28) months. The 1-year, 2-year, 3-year and 5-year survival rates of high-grade gliomapatients were 87.50%, 56.25%, 40.63% and 17.19%, respectively. The univariate analysis of Log-Rank test and the Cox regression model analysis showed that the prognostic factors related to the prognosis of high-grade gliomapatients were pathological grade, resection degree, and concurrent chemo-radiotherapy (P<0.05). Conclusion: The overall survival time, progression-free survival time and the 5-year survival rate of patients with high-grade glioma after comprehensive treatment is partially improved. The factors relevant to the prognosis of patients with high-grade glioma are pathological grade, resection degree, and concurrent chemo-radiotherapy, indicating that the gliomapatients (WHO grade III) received total resection of the tumor and concurrent chemo-radiotherapy have better clinical effect.